The polypill and cardiovascular disease. by Fahey, Tom et al.
Fahey, T; Brindle, P; Ebrahim, S (2005) The polypill and cardiovas-
cular disease. BMJ, 330 (7499). pp. 1035-6. ISSN 1468-5833 DOI:
10.1136/bmj.330.7499.1035
Downloaded from: http://researchonline.lshtm.ac.uk/12765/
DOI: 10.1136/bmj.330.7499.1035
Usage Guidelines
Please refer to usage guidelines at http://researchonline.lshtm.ac.uk/policies.html or alterna-
tively contact researchonline@lshtm.ac.uk.
Available under license: Creative Commons Attribution Non-commercial
http://creativecommons.org/licenses/by-nc/2.5/
The polypill and cardiovascular disease
May be appropriate for secondary, but perhaps not for primary prevention
The prevention of cardiovascular disease withdrug therapy is well known. Randomisedcontrolled trials and meta-analyses of trials of
lipid and blood pressure lowering and antiplatelet
therapy have established their efficacy in the prevention
of cardiovascular diseases.Wald and Law have proposed
that these three treatments, along with folic acid, be
combined into a “polypill.”1 They propose a combined
strategy for primary and secondary prevention—
targeting all people with pre-existing cardiovascular dis-
ease (secondary prevention) but more controversially,
targeting all adults aged over 55 (primary prevention) as
well. The underlying assumption concerning the efficacy
of this strategy is that the six individual ingredients of the
polypill (thiazide diuretic, angiotensin converting
enzyme inhibitor,  blocker, statin, aspirin, and folic acid)
when combined together have synergistic treatment
effects—calculated by multiplying the relative risk reduc-
tions on each class of treatment. Their polypill strategy
has generated worldwide interest, with some critics
questioning this underlyingmultiplicative assumption as
being too optimistic.
For these reasons, the paper by Hippisley-Cox and
Coupland in this issue (p 1059), examining the
individual and combined effects of three of the polypill
ingredients—statins, aspirin, and blood pressure lower-
ing drugs is timely.2 Their analysis provides support for
the synergic action of the polypill in the context of sec-
ondary prevention of coronary heart disease. Their
analysis of 11 330 patients with coronary heart disease
shows that all cause mortality is lower in those patients
taking drug combinations—two or three drugs when
compared with those taking single agents. These
findings are consistent with a previous study that showed
that a combination of two drugs, aspirin and pravastatin,
is superior to either drug alone in the secondary
prevention of cardiovascular disease.3 A further study of
dispensed prescribing in the secondary prevention of
coronary heart disease in 4892 patients in Tayside, Scot-
land, also shows that patients taking an additional
cardiovascular drug experience fewer cardiovascular
events than patients taking statins alone, but that this
synergistic effect was not sustained when two additional
drugs were taken: hazard ratios for combinations of two
and three drugs were the same.4 Overall these studies
provide support for the synergistic effects of two, but not
three or four, drug combinations in secondary
prevention. However, these studies are non-randomised
comparisons of outcomes and are therefore prone to
confounding by severity of disease and other factors.
In the context of primary prevention many
uncertainties remain. Recent evidence concerning the
differential effect of aspirin in women compared with
men is emerging. While the efficacy of aspirin in men is
established,5 the recently completed women’s health
study, of low dose aspirin (100mg every other day) com-
pared with placebo, did not produce a reduction in all
cause mortality or fatal and non-fatal myocardial infarc-
tion.6 Although observational evidence favours a
possible causal association between raised plasma
homocysteine concentrations and cardiovascular dis-
ease,7 this association has been described as modest; a
25% reduction in usual homocysteine concentrations is
associated with a 11% lower risk of coronary heart
disease and a 19% lower risk of stroke.8 We have growing
evidence from approaches using mendelian randomisa-
tion that the expected effects of the folic acid
component may not be confirmed.9 Furthermore, a
recent randomised trial of 2.5 mg/day of folic acid (the
proposed polypill dosage is 0.8 mg/day) was not associ-
ated with a reduction in the combined trial end point of
stroke, coronary events, and death in patients who has
previously had a cerebral infarction.10 In the light of con-
flicting evidence between observational and randomised
controlled studies concerning the benefits of antioxidant
vitamins and prevention of cardiovascular disease,
caution is needed before extrapolating the benefits from
observational studies to benefit from treatment with the
folic acid component of the polypill.11
Other concerns about the primary prevention
strategy of the polypill relate to its non-specific scatter-
shot primary prevention approach, which would
expose people at lower risk to lifelong treatment, with
attendant medicalising of the population.12 Cost effec-
tiveness analyses that estimated the impact of
cardiovascular risk in the strategy to treat hypertension
have shown that treating individuals at high risk is
highly cost effective, irrespective of age or sex.
However, individuals at lower risk (who represent most
of the adult population) are much more expensive to
treat in terms of gain in quality adjusted life years.13
Furthermore, the preference of patients has a strong
bearing on the cost effectiveness of treatment in these
low risk individuals.13
The underlying tenet of the polypill—that combina-
tion therapy is better than monotherapy—may well be
correct, particularly with regard to secondary preven-
tion of cardiovascular disease. Hippisley-Cox and
Coupland’s paper goes some way in providing data
concerning the effects of combined treatment in
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secondary prevention of coronary heart disease. In
terms of primary prevention, development and testing
of combination pills aimed at reducing more than one
risk factor seems entirely logical, particularly in the
context of assessment of global cardiovascular risk.
Funding bodies and the NHS need to support the nec-
essary trials and cost effectiveness studies to further
examine the polypill strategy in comparison with non-
pharmacological alternatives.
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Pharmacogenetics and ethnically targeted therapies
New drug BiDil marks the return of biology to the debate about race and ethnicity
In modern conceptions of race and ethnicity,biology has been relegated to a minor underlyingfactor.1 Instead, these concepts have been cast as
largely social constructions.2 For example, race
traditionally distinguishes between groups according
to a mixture of physical characteristics (including skin
colour), which reflect ancestry and hence biology. A
modern conception of race would place the emphasis
on a common social and political heritage. Similarly,
ethnicity puts emphasis on distinguishing between
groups by using a mixture of cultural factors, including
language and religion.2 Recent developments in phar-
macogenetics, however, renew the historical emphasis
on biology in concepts of race and ethnicity.
Pharmacogeneticists examine whether different
responses to drug treatment may be attributable to
genetic differences. They are focusing on race and eth-
nicity as a means to this end. A recent international
conference, the 8th world congress on clinical
pharmacology and therapeutics, in Brisbane, Australia,
had an afternoon on ethnopharmacology, showing
how seriously this new subject is being taken.3
In the middle of this resurgence of the role of biol-
ogy in concepts of race and ethnicity comes BiDil, a
new drug treatment for heart failure tested solely in
one particular racial group. In 2001 NitroMed began
the African-American heart failure trial (A-HeFT), the
first heart failure trial conducted exclusively in
African-American patients, claiming that “observed
racial disparities in mortality and therapeutic response
rates in Black heart failure patients may be due in part
to ethnic differences in the underlying pathophysiol-
ogy of heart failure.”4 5 The study found that BiDil (a
fixed dose of isosorbide dinitrate and hydralazine,
designed to restore low or depleted nitric oxide
concentrations to the blood) combined with standard
therapy for heart failure reduced mortality by 43%
among black patients.5 Hailed by the media as the first
ethnic drug, BiDil is reported to be on the way to
becoming the first drug approved by the US Food and
Drug Administration to treat heart failure in
African-American patients only.6
The major implication of BiDil is that differential
responses to treatment between racial groups, defined
by using ostensibly social categories (here, patients self
reported to be African-Americans), are attributed
primarily to genetic differences. If this is shown to be
true it will undermine a postwar consensus emphasis-
ing the social construction of race and ethnicity.
Largely social categories of race and ethnicity may be
useful indicators of genetic variations because they are
at least partly based on biological characteristics. If
everyone were the same physically—skin colour and so
on—racial and ethnic categories would not exist. This
raises fundamental and controversial questions. Do
important genetic differences exist between ethnic and
racial groups as defined by current classifications? If
they do, how good are current racial labels as an indi-
cator of these genetic differences? Should such classifi-
cations be used in this way? If so, will race science see a
resurgence?1
Many researchers and policy makers argue against
the use of racial or ethnic categories in medicine,
saying that classifying people according to race and
ethnicity reinforces existing social divisions in society
or leads to discriminatory practices.7 Others cite
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